<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00968695</url>
  </required_header>
  <id_info>
    <org_study_id>IG0802</org_study_id>
    <nct_id>NCT00968695</nct_id>
  </id_info>
  <brief_title>Effects of Long Term Albumin 20% Administration in Patients With Cirrhosis and Ascites.</brief_title>
  <official_title>Clinical Trial on the Effects of Long Term Administration of 20% Albumin in the Cardiovascular and Renal Function, And Hepatic Hemodynamics in Advanced Patients With Cirrhosis and Ascites.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Grifols, S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grifols Therapeutics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effects of long term albumin administration on the cardiocirculatory and renal function and
      hepatic hemodynamics in patients with advanced cirrhosis and ascites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pharmacodynamic study of pathophysiological nature to assess the effects of prolonged
      administration of human albumin in the cardiocirculatory and renal function and hepatic
      hemodynamics in patients with advanced cirrhosis and ascites.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To asses change from Baseline plasma renin concentration at Week 14</measure>
    <time_frame>14 weeks</time_frame>
    <description>Plasma renin activity will be measured at Baseline and Week 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To asses change from Baseline plasma renin concentration at Week 20</measure>
    <time_frame>20 weeks</time_frame>
    <description>Plasma renin activity will be measured at Baseline and Week 20</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To asses change from Baseline plasma concentration of noradrenaline at week 14</measure>
    <time_frame>14 weeks</time_frame>
    <description>Plasma noradrenaline concentration will be measured at Baseline and Week 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To asses change from Baseline plasma concentration of noradrenaline at Week 20</measure>
    <time_frame>20 weeks</time_frame>
    <description>Plasma noradrenaline concentration will be measured at Baseline and Week 20</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess change from Baseline glomerular filtration rate at Week 14</measure>
    <time_frame>14 weeks</time_frame>
    <description>Glomerular filtration rate will be measured at Baseline and Week 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess change from Baseline glomerular filtration rate at Week 20</measure>
    <time_frame>20 weeks</time_frame>
    <description>Glomerular filtration rate will be measured at Baseline and Week 20</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess change from Baseline cardiac output at Week 14</measure>
    <time_frame>14 weeks</time_frame>
    <description>Cardiac output will be measured at Baseline and Week 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess change from Baseline cardiopulmonary pressures at Week 14</measure>
    <time_frame>14 weeks</time_frame>
    <description>Cardiopulmonary pressures will be measured at Baseline and Week 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess change from Baseline free hepatic pressure at Week 14</measure>
    <time_frame>14 weeks</time_frame>
    <description>Free hepatic pressure will be measured at Baseline and Week 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess change from Baseline wedged hepatic pressure at Week 14</measure>
    <time_frame>14 weeks</time_frame>
    <description>Wedged hepatic pressure will be measured at Baseline and Week 14</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess change from Baseline echocardiography at Week 14</measure>
    <time_frame>14 weeks</time_frame>
    <description>Echocardiography will be measured at Baseline and Week 14</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>Albumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be receiving albumin 20% infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>The pattern of administration of 20% human albumin is 1.5g/kg every week to be infused in 6 hours with a minimum of 90g up and a maximum of 150g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.</description>
    <arm_group_label>Albumin</arm_group_label>
    <other_name>Albutein 20%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above 18 years and less than 80 years.

          -  Diagnosis of liver cirrhosis by biopsy or by clinical, laboratory, or ultrasound.

          -  Daily requirement of diuretics at least 200mg of spironolactone or 100mg of
             spironolactone and 40 mg of furosemide

          -  Renal dysfunction defined by a plasma concentration of serum creatinine ≥ 1.2 mg / dl,
             blood urea nitrogen ≥ 25 mg / dl or a serum sodium concentration ≤ 130 mEq / L.

        Exclusion Criteria:

          -  Refractory Ascites (paracentesis requirements over 1 month.

          -  Neoplastic disease including liver cancer if it exceeds the Milan criteria (one
             nodule&gt; 5 cm or three nodules&gt; 3 cm).

          -  History of transjugular intrahepatic portosystemic shunt (TIPS) or surgical shunt

          -  Gastrointestinal bleeding or bacterial infection documented in the past 15 days.

          -  Heart failure or structural heart disease.

          -  Organic renal insufficiency(proteinuria, hematuria and / or ultrasound data
             nephropathy).

          -  Moderate or severe lung chronic disease.

          -  Transplant.

          -  Infection with human immunodeficiency virus.

          -  Active addiction to drugs.

          -  Mental state that prevents the patient understand the nature, extent and consequences
             of the study, except for hepatic encephalopathy.

          -  Pregnancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicente Arroyo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>August 28, 2009</study_first_submitted>
  <study_first_submitted_qc>August 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2009</study_first_posted>
  <last_update_submitted>June 24, 2019</last_update_submitted>
  <last_update_submitted_qc>June 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

